Found 4 articles for: "Triple-Combination"
Assessing Cutibacterium Acnes Susceptibility With Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel Use: Six-Month Analysis
November 2025 | Volume 24 | Issue 11 | Original Article | 1106 | Copyright © November 2025
Background: The only approved triple-combination acne treatment – clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% (CAB) gel - demonstrated efficacy/safety ...
Read MoreSafety and Tolerability of Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Truncal Acne
August 2025 | Volume 24 | Issue 8 | Original Article | 803 | Copyright © August 2025
Background: Truncal acne is underdiagnosed and undertreated, and it can lead to scarring and postinflammatory hyperpigmentation. However, applying topical treatments to larger sk...
Read MoreApplication Characteristics and Patient Preference of Triple-Combination vs Layered Topicals for Acne: Split-Face Study
October 2024 | Volume 23 | Issue 10 | Original Article | 857 | Copyright © October 2024
Background: Although triple-combination therapies for acne are generally more efficacious than dual-combinations or topical monotherapy, this benefit may be offset by reduced adh...
Read MoreTriple-Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Acne in Adult and Pediatric Participants
June 2024 | Volume 23 | Issue 6 | Original Article | 394 | Copyright © June 2024
Background: Topical clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel (CAB) is the first fixed-dose triple-combination approved for the treatment of acne. This...
Read More© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
